ジフテリア・百日咳・破傷風(DTP)ワクチンの世界市場2020–2027:製品タイプ別(DTaPワクチン(ジフテリア-破傷風-無細胞百日咳ワクチン)、TD(破傷風-ジフテリア-無菌性百日咳)ワクチン、Tdap(破傷風-ジフテリア-無菌性百日咳)ワクチン)、年齢別、エンドユーザー別

【英語タイトル】Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market by Product Type (DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (Tetanus and Diphtheria) vaccine, and Tdap (Tetanus-Diphtheria-Acellular Pertussis) vaccine, by Age Group (Adult and Pediatric), and by End User (Hospitals, Clinics, and Vaccination Centers): Global Opportunity Analysis and Industry Forecast, 2020–2027

Allied Market Researchが出版した調査資料(AMR20JL058)・商品コード:AMR20JL058
・発行会社(調査会社):Allied Market Research
・発行日:2020年5月
・ページ数:193
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:生命科学
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥569,220見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥683,700見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥953,470見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、ジフテリア・百日咳・破傷風(DTP)ワクチンの世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、製品タイプ別(DTaPワクチン(ジフテリア-破傷風-無細胞百日咳ワクチン)、TD(破傷風-ジフテリア-無菌性百日咳)ワクチン、Tdap(破傷風-ジフテリア-無菌性百日咳)ワクチン)分析、年齢別分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。
・イントロダクション
・エグゼクティブサマリー
・市場動向
・ジフテリア・百日咳・破傷風(DTP)ワクチンの世界市場規模:製品タイプ別(DTaPワクチン(ジフテリア-破傷風-無細胞百日咳ワクチン)、TD(破傷風-ジフテリア-無菌性百日咳)ワクチン、Tdap(破傷風-ジフテリア-無菌性百日咳)ワクチン)
・ジフテリア・百日咳・破傷風(DTP)ワクチンの世界市場規模:年齢別
・ジフテリア・百日咳・破傷風(DTP)ワクチンの世界市場規模:エンドユーザー別
・ジフテリア・百日咳・破傷風(DTP)ワクチンの世界市場規模:地域別
・企業情報
【レポートの概要】

The global diphtheria, pertussis, and tetanus (DTP) vaccine market was valued at $ 4,758.8 million in 2019 and is expected to reach $ 7,054.4 million by 2027, with a CAGR of 5.1% during the forecast period.

Diphtheria, tetanus, and pertussis or DTP, are serious diseases caused by bacteria. DTP vaccine is a blend of diphtheria and tetanus toxoids adsorbed with pertussis vaccine for intramuscular vaccination. Diphtheria and tetanus toxoids and pertussis vaccine are recommended simultaneously for successful immunization of children up to seven years of age against diphtheria, tetanus, and pertussis (whooping cough) provide an impactful boost to the market growth. Approximately 86 % of infants worldwide (116.3 million children) received 3 doses of diphtheria-tetanus-pertussis 3 (DTP3) vaccine during 2018, shielding them from infectious diseases that may cause severe illness and disability, or could even be fatal. .

In 2017, the global demand for all D&T containing vaccines was estimated at around 945 million doses. Self-procuring countries represent almost half of the global demand for DTP vaccines. The WHO has recommended a life course of six doses of diphtheria and tetanus containing vaccines throughout the world. Thus, established firms are currently devoting almost 5% of their total R&D expenditure in vaccine development. Since last decade, biotech firms have emerged as a new force in the area of early stage product development and applied vaccine research. Players operating in the DTP vaccines market are mostly focused on establishing a strong network with dealers and their distributors. Players are partnering with other vaccine manufacturing companies to enhance their product portfolio as well as to expand their global reach. Vaccine development technology has witnessed a revolutionary growth, and has led to the expansion of innovative and new diagnostic technologies with various advancements in therapeutic applications.

The report classifies the global DTP vaccines market based on products, age group, end users, and region. By product, it is categorized into a DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (tetanus and diphtheria) vaccine, and Tdap (Tetanus-diphtheria-acellular Pertussis vaccine). By age group, it is divided into adult and pediatric. By end users, it is categorized into hospitals, clinics, and vaccination centers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

ü This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.
ü An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
ü A comprehensive analysis of the factors that drive and restrain the growth of the global DTP Vaccine market is provided.
ü An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

• By Product Type

o DTaP
o TD
o Tdap

• By Age Group
o Adult
o Pediatric

• By End User
o Hospitals
o Clinics
o Vaccination Centers

• By Region
o North America
• U.S.
• Canada
• Mexico
o Europe
• Germany
• France
• UK
• Italy
• Rest of Europe
o Asia-Pacific
• Japan
• China
• Australia
• India
• Rest of Asia-Pacific
o LAMEA
• Brazil
• South Africa
• Rest of LAMEA

KEY MARKET PLAYERS

• AJ Vaccines
• Bionet-Asia
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Massbiologics
• Meiji Holdings Co., Ltd. (KM biologics co., Ltd.)
• Merck & Co., Inc.
• Panacea Biotec Ltd.
• Sanofi
• Serum Institute of India Pvt. Ltd

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top player positioning, 2019

3.3.Porter’s five forces analysis
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Rise in initiatives by pharma companies to enhance vaccine R&D
3.4.1.2.Growth in awareness among people about the advantages of DTP vaccines

3.4.2.Restraints

3.4.2.1.Inadequate access to vaccines in under developed countries
3.4.2.2.High cost of vaccine development

3.4.3.Opportunities

3.4.3.1.Innovative vaccine technologies

CHAPTER 4:DTP VACCINES MARKET, BY PRODUCT TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.DTaP Vaccines

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country

4.3.TD Vaccines

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Tdap Vaccines

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:DTP VACCINES MARKET, BY AGE GROUP

5.1.Overview

5.1.1.Market size and forecast

5.2.Adults

5.2.1.Market size and forecast
5.2.2.Market analysis, by country

5.3.Pediatrics

5.3.1.Market size and forecast
5.3.2.Market analysis, by country

CHAPTER 6:DTP VACCINES MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast
6.2.2.Market analysis, by country

6.3.Clinics

6.3.1.Market size and forecast
6.3.2.Market analysis, by country

6.4.Vaccination Centers

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

CHAPTER 7:DTAP VACCINES MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by product
7.2.3.Market size and forecast, by age group
7.2.4.Market size and forecast, by end user
7.2.5.Market size and forecast, by country

7.2.5.1.U.S. market size and forecast, by product
7.2.5.2.U.S. market size and forecast, by age group

7.2.6.Market size and forecast, by end users

7.2.6.1.Canada market size and forecast, by product
7.2.6.2.Canada market size and forecast, by age group

7.2.7.Market size and forecast, by end users

7.2.7.1.Mexico market size and forecast, by product
7.2.7.2.Mexico market size and forecast, by age group

7.2.8.Market size and forecast, by end users

7.3.Europe

7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by product
7.3.3.Market size and forecast, by age group
7.3.4.Market size and forecast, by end user
7.3.5.Market size and forecast, by country

7.3.5.1.Germany market size and forecast, by product
7.3.5.2.Germany market size and forecast, by age group

7.3.6.Market size and forecast, by end users

7.3.6.1.France market size and forecast, by product
7.3.6.2.France market size and forecast, by age group

7.3.7.Market size and forecast, by end users

7.3.7.1.UK market size and forecast, by product
7.3.7.2.UK market size and forecast, by age group

7.3.8.Market size and forecast, by end users

7.3.8.1.Italy market size and forecast, by product
7.3.8.2.Italy market size and forecast, by age group

7.3.9.Market size and forecast, by end users

7.3.9.1.Rest of Europe market size and forecast, by product
7.3.9.2.Rest of Europe market size and forecast, by age group

7.3.10.Market size and forecast, by end users

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by product
7.4.3.Market size and forecast, by age group
7.4.4.Market size and forecast, by end users
7.4.5.Market size and forecast, by country

7.4.5.1.Japan market size and forecast, by product
7.4.5.2.Japan market size and forecast, by age group

7.4.6.Market size and forecast, by end users

7.4.6.1.China market size and forecast, by product
7.4.6.2.China market size and forecast, by age group

7.4.7.Market size and forecast, by end users

7.4.7.1.Australiamarket size and forecast, by product
7.4.7.2.Australia market size and forecast, by age group

7.4.8.Market size and forecast, by end users

7.4.8.1.India market size and forecast, by product
7.4.8.2.India market size and forecast, by age group

7.4.9.Market size and forecast, by end users

7.4.9.1.Rest of Asia Pacificmarket size and forecast, by product
7.4.9.2.Rest of Asia Pacific market size and forecast, by age group

7.4.10.Market size and forecast, by end users

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by product
7.5.3.Market size and forecast, by age group
7.5.4.Market size and forecast, by end users
7.5.5.Market size and forecast, by country

7.5.5.1.Brazil market size and forecast, by product
7.5.5.2.Brazil market size and forecast, by age group

7.5.6.Market size and forecast, by end users

7.5.6.1.South Africa market size and forecast, by product
7.5.6.2.South Africa market size and forecast, by age group

7.5.7.Market size and forecast, by end users

7.5.7.1.Rest of LAMEA market size and forecast, by product
7.5.7.2.Rest of LAMEA market size and forecast, by age group
7.5.8.Market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.AJ VACCINES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio

8.2.BIONET-ASIA

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio

8.3.GLAXOSMITHKLINE PLC (GSK)

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.JOHNSON & JOHNSON

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.MASSBIOLOGICS

8.5.1.Company overview
8.5.2.Company snapshot1
8.5.3.Product portfolio

8.6.MEIJI HOLDINGS CO., LTD. (KM BIOLOGICS CO., LTD.)

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.MERCK & CO., INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.PANACEA BIOTEC LTD.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.SANOFI

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.SERUM INSTITUTE OF INDIA PVT. LTD

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio

LIST OF TABLES

TABLE 01.GLOBAL DTP VACCINES MARKET, BY PRODUCT TYPE 2019–2027, ($MILLION)
TABLE 02.DTAP VACCINES MARKET, BY REGION, 2019–2027, ($MILLION
TABLE 03.TD VACCINES MARKET, BY REGION, 2019–2027, ($MILLION)
TABLE 04.TDAP VACCINES MARKET, BY REGION, 2019–2027, ($MILLION)
TABLE 05.GLOBAL DTP VACCINES MARKET, BY AGE GROUP, 2019–2027, ($MILLION)
TABLE 06.DTP VACCINES MARKET FOR ADULTS, BY REGION, 2019–2027, ($MILLION)
TABLE 07.DTP VACCINES MARKET FOR PEDIATRICS, BY REGION, 2019–2027, ($MILLION)
TABLE 08.GLOBAL DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 09.DTP MARKET FOR HOSPITALS, BY REGION, 2019–2027, ($MILLION)
TABLE 10.DTP MARKET FOR CLINICS, BY REGION, 2019–2027, ($MILLION)
TABLE 11.DTP MARKET FOR VACCINATION CENTERS, BY REGION, 2019–2027, ($MILLION)
TABLE 12.DTP VACCINES MARKET, BY REGION 2019–2027, ($MILLION)
TABLE 13.NORTH AMERICA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 14.NORTH AMERICA VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 15.NORTH AMERICA VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 16.NORTH AMERICA DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 17.U.S. DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 18.U.S. DTAP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 19.U.S. DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 20.CANADA DTP VACCINES MARKET, BY PRODUCT, 2019-2026, ($MILLION)
TABLE 21.CANADA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 22.CANADA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 23.MEXICO DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 24.MEXICO DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 25.MEXICO DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 26.EUROPE DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 27.EUROPE DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 28.EUROPE DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 29.EUROPE DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 30.GERMANY DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 31.GERMANY DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 32.GERMANY DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 33.FRANCE DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 34.FRANCE DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 35.FRANCE DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 36.UK DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 37.UK DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 38.UK DTP VACCINES MARKET, BY END USER, , 2019-2027, ($MILLION)
TABLE 39.ITALY DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 40.ITALY DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 41.ITALY DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 42.REST OF EUROPE DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 43.REST OF EUROPE DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 44.REST OF EUROPE DTAP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 45.ASIA-PACIFIC DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 46.ASIA-PACIFIC DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 47.ASIA-PACIFIC DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 48.ASIA-PACIFIC DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 49.JAPAN DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 50.JAPAN DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 51.JAPAN DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 52.CHINA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 53.CHINA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 54.CHINA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 55.AUSTRALIADTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 56.AUSTRALIA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 57.AUSTRALIADTAP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 58.INDIADTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 59.INDIADTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 60.INDIADTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 61.REST OF ASIA PACIFICDTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 62.REST OF ASIA PACIFICDTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 63.REST OF ASIA PACIFICDTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 64.LAMEA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 65.LAMEA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 66.LAMEA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 67.LAMEA DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 68.BRAZIL DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 69.BRAZIL DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 70.BRAZIL DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 71.SOUTH AFRICA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 72.SOUTH AFRICA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 73.SOUTH AFRICA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 74.REST OF LAMEA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 75.REST OF LAMEA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 76.REST OF LAMEA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 01.AJ VACCINES: COMPANY SNAPSHOT
TABLE 02.AJ VACCINE: PRODUCT PORTFOLIO
TABLE 03.BIONET-ASIA: COMPANY SNAPSHOT
TABLE 04.BIONET-ASIA: PRODUCT PORTFOLIO
TABLE 05.GSK: COMPANY SNAPSHOT
TABLE 06.GLAXOSMITHKLINE PLC.: OERATING SEGMENT
TABLE 07.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 08.J&J: COMPANY SNAPSHOT
TABLE 09.J&J: OPERATING SEGMENTS
TABLE 10.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 11.MASSBIOLOGICS: COMPANY SNAPSHOT
TABLE 12.MASSBIOLOGICS: PRODUCT PORTFOLIO
TABLE 13.MEIJI.: COMPANY SNAPSHOT
TABLE 14.MEIJI HOLDINGS CO., LTD..: OPERATING SEGMENTS
TABLE 15.MEIJI HOLDINGS CO., LTD.: PRODUCT PORTFOLIO
TABLE 16.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 17.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 18.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 19.PANACEA BIOTEC LTD..: COMPANY SNAPSHOT
TABLE 20.PANACEA BIOTEC LTD..: OPERATING SEGMENTS
TABLE 21.PANACEA BIOTEC LTD.: PRODUCT PORTFOLIO
TABLE 22.PANACEA BIOTEC LTD..: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 23.SANOFI: COMPANY SNAPSHOT
TABLE 24.SANOFI: OERATING SEGMENT
TABLE 25.SANOFI: PRODUCT PORTFOLIO
TABLE 26.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 27.SII.: COMPANY SNAPSHOT
TABLE 28.SII.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.DTP VACCINES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN DTP VACCINE MARKET, 2019
FIGURE 03.TOP PLAYER POSITIONING, 2019
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.HIGH BARGAINING POWER OF BUYERS
FIGURE 06.LOW THREAT OF SUBSTITUTIONS
FIGURE 07.MODERATE THREAT OF NEW ENTRANTS
FIGURE 08.MODERATE COMPETITIVE RIVALRYS
FIGURE 09.GLOBAL DTP VACCINE MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 10.COMPARATIVE SHARE ANALYSIS OF DTAP VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 11.COMPARATIVE SHARE ANALYSIS OF TDAP VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF TDAP VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR ADULTS, BY COUNTRY,
2019 & 2027 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR PEDIATRICS, BY COUNTRY,
2019 & 2027 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR HOSPITALS, BY COUNTRY,
2019 & 2027 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR CLINICS, BY COUNTRY,
2019 & 2027 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR VACCINATION CENTERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 01.GSK NET SALES, 2017–2019 ($MILLION)
FIGURE 02.GLAXOSMITHKLINE PLC.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 03.GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 04.JOHNSON & JOHNSON: NET SALES, 2017–2019 ($MILLION)1
FIGURE 05.JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 06.JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 07.MEIJI HOLDINGS CO., LTD.: NET SALES, 2017–2019 ($MILLION)
FIGURE 08.MEIJI HOLDINGS CO., LTD.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 09.MERCK & CO., INC.: NET SALES, 2016–2018 ($MILLION)
FIGURE 10.MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 11.MERCK & CO., INC.: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 12.PANACEA BIOTEC LTD.: NET SALES, 2017–2019 ($MILLION)
FIGURE 13.PANACEA BIOTEC LTD.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 14.PANACEA BIOTEC LTD.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 15.SANOFI.: NET SALES, 2017–2019 ($MILLION)
FIGURE 16.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 17.SANOFI: REVENUE SHARE BY REGION, 2019 (%)

★調査レポート[ジフテリア・百日咳・破傷風(DTP)ワクチンの世界市場2020–2027:製品タイプ別(DTaPワクチン(ジフテリア-破傷風-無細胞百日咳ワクチン)、TD(破傷風-ジフテリア-無菌性百日咳)ワクチン、Tdap(破傷風-ジフテリア-無菌性百日咳)ワクチン)、年齢別、エンドユーザー別] (コード:AMR20JL058)販売に関する免責事項を必ずご確認ください。
★調査レポート[ジフテリア・百日咳・破傷風(DTP)ワクチンの世界市場2020–2027:製品タイプ別(DTaPワクチン(ジフテリア-破傷風-無細胞百日咳ワクチン)、TD(破傷風-ジフテリア-無菌性百日咳)ワクチン、Tdap(破傷風-ジフテリア-無菌性百日咳)ワクチン)、年齢別、エンドユーザー別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆